Daiichi Sankyo

Exelixis to Release Third Quarter 2021 Financial Results on Tuesday, November 2, 2021

Tuesday, October 19, 2021 - 9:05pm

Exelixis, Inc. (Nasdaq: EXEL) announced today that its third quarter 2021 financial results will be released on Tuesday, November 2, 2021 after the markets close.

Key Points: 
  • Exelixis, Inc. (Nasdaq: EXEL) announced today that its third quarter 2021 financial results will be released on Tuesday, November 2, 2021 after the markets close.
  • At 5:00 p.m. EDT / 2:00 p.m. PDT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update.
  • For more information about Exelixis, please visit www.exelixis.com , follow @ExelixisInc on Twitter or like Exelixis, Inc. on Facebook.
  • Exelixis, the Exelixis logo, CABOMETYX, COMETRIQ and COTELLIC are registered trademarks of Exelixis, Inc. MINNEBRO is a registered trademark of Daiichi Sankyo Company, Limited.

Insights from the world's leading KOLs on the prospects of launched and pipeline therapies for non-small cell lung cancer

Thursday, October 14, 2021 - 3:45pm

A comprehensive, qualitative review of targeted and novel therapies in the non-small cell lung cancer.

Key Points: 
  • A comprehensive, qualitative review of targeted and novel therapies in the non-small cell lung cancer.
  • In-depth interviews were conducted with 12 of the world's foremost KOLs in the United States and Europe.
  • How do KOLs assess Turning Point's pipeline repotrectinib and AnHeart's taletrectinib in the treatment of ROS1-positive NSCLC?
  • Why do KOLs expect Eli Lilly's late-stage Retevmo/Retsevmo and Blueprint Medicines/Roche's Gavreto will become front-line treatments for RET-fusion positive NSCLC?

Exelixis In-Licenses Second Anti-Cancer Compound from Aurigene Following FDA Acceptance of Investigational New Drug Application for Phase 1 Clinical Trial in Non-Hodgkin’s Lymphoma

Thursday, October 14, 2021 - 1:00pm

Exelixis has now assumed responsibility for the future clinical development, commercialization and global manufacturing of XL114.

Key Points: 
  • Exelixis has now assumed responsibility for the future clinical development, commercialization and global manufacturing of XL114.
  • Following the U.S. Food and Drug Administrations (FDA) recent acceptance of its Investigational New Drug (IND) application, Exelixis will soon initiate a phase 1 clinical trial evaluating XL114 monotherapy in patients with Non-Hodgkins lymphoma (NHL).
  • View the full release here: https://www.businesswire.com/news/home/20211014005549/en/
    XL114 is the second molecule that Exelixis in-licensed from Aurigene under the companies July 2019 collaboration, option and license agreement.
  • Exelixis, the Exelixis logo, CABOMETYX, COMETRIQ and COTELLIC are registered trademarks of Exelixis, Inc. MINNEBRO is a registered trademark of Daiichi Sankyo Company, Limited.

Exelixis and STORM Therapeutics Enter into Exclusive Collaboration and License Agreement to Discover and Develop Inhibitors of Novel RNA Modifying Enzymes

Thursday, October 14, 2021 - 1:30pm

The collaboration will focus initially on ADAR1, advancing early work by STORM applying its proprietary RNA epigenetic platform, as well as explore an additional undisclosed target.

Key Points: 
  • The collaboration will focus initially on ADAR1, advancing early work by STORM applying its proprietary RNA epigenetic platform, as well as explore an additional undisclosed target.
  • "STORM has established industry-leading expertise and know-how through ground-breaking research on the discovery of small molecule therapies targeting RNA-modifying enzymes.
  • This collaboration with Exelixis validates the significant value of our technology platform and expanding pipeline," said Keith Blundy, Director and Chief Executive Officer, STORM Therapeutics.
  • Exelixis, the Exelixis logo, CABOMETYX, COMETRIQ and COTELLIC are registered U.S. trademarks of Exelixis, Inc. MINNEBRO is a registered trademark of Daiichi Sankyo Company, Limited.

Exelixis and STORM Therapeutics Enter into Exclusive Collaboration and License Agreement to Discover and Develop Inhibitors of Novel RNA Modifying Enzymes

Thursday, October 14, 2021 - 1:30pm

ALAMEDA, Calif. and CAMBRIDGE, England, Oct. 14, 2021 /PRNewswire/ -- Exelixis, Inc. (Nasdaq: EXEL) and STORM Therapeutics (STORM) today announced that they have entered into an exclusive collaboration and license agreement under which the parties will discover and advance novel drug leads intended for the treatment of cancer. The collaboration will focus initially on ADAR1, advancing early work by STORM applying its proprietary RNA epigenetic platform, as well as explore an additional undisclosed target. 

Key Points: 
  • The collaboration will focus initially on ADAR1, advancing early work by STORM applying its proprietary RNA epigenetic platform, as well as explore an additional undisclosed target.
  • "STORM has established industry-leading expertise and know-how through ground-breaking research on the discovery of small molecule therapies targeting RNA-modifying enzymes.
  • This collaboration with Exelixis validates the significant value of our technology platform and expanding pipeline," said Keith Blundy, Director and Chief Executive Officer, STORM Therapeutics.
  • Exelixis, the Exelixis logo, CABOMETYX, COMETRIQ and COTELLIC are registered U.S. trademarks of Exelixis, Inc. MINNEBRO is a registered trademark of Daiichi Sankyo Company, Limited.

Exelixis and STORM Therapeutics Enter into Exclusive Collaboration and License Agreement to Discover and Develop Inhibitors of Novel RNA Modifying Enzymes

Thursday, October 14, 2021 - 1:00pm

Exelixis, Inc. (Nasdaq: EXEL) and STORM Therapeutics (STORM) today announced that they have entered into an exclusive collaboration and license agreement under which the parties will discover and advance novel drug leads intended for the treatment of cancer.

Key Points: 
  • Exelixis, Inc. (Nasdaq: EXEL) and STORM Therapeutics (STORM) today announced that they have entered into an exclusive collaboration and license agreement under which the parties will discover and advance novel drug leads intended for the treatment of cancer.
  • STORM has established industry-leading expertise and know-how through ground-breaking research on the discovery of small molecule therapies targeting RNA-modifying enzymes.
  • This collaboration with Exelixis validates the significant value of our technology platform and expanding pipeline, said Keith Blundy, Director and Chief Executive Officer, STORM Therapeutics.
  • Exelixis, the Exelixis logo, CABOMETYX, COMETRIQ and COTELLIC are registered U.S. trademarks of Exelixis, Inc. MINNEBRO is a registered trademark of Daiichi Sankyo Company, Limited.

DGAP-News: Defence Therapeutics Inc.: DEFENCE THERAPEUTICS ACCUMTM VARIANTS IN VITRO STUDY INCREASES THE POTENCY OF T-DERUXTECAN ADC BY 5-FOLD ON BREAST CANCER

Wednesday, October 13, 2021 - 8:02am

Defence has successfully selected and tested 5 AccumTM variants to the T-deruxtecan ADC Therapeutic.

Key Points: 
  • Defence has successfully selected and tested 5 AccumTM variants to the T-deruxtecan ADC Therapeutic.
  • The 5 selected Accum-T-deruxtecan increases the potency of T-deruxtecan ADC Therapeutic by approximatively 5-fold on the HER2 positive breast cancer Trastuzumab and T-DM1 resistant cell line model named JIMT-1.
  • The 5 selected AccumTM variants will be sent to our collaborator at the HUS Comprehensive Cancer Center in Helsinki, Finland for the optimization of Defence's Accum-T-deruxtecan ADC Therapeutic.
  • Defence Therapeutics is a publicly-traded biotechnology company working on engineering the next generation vaccines and ADC products using its proprietary platform.

AI-Powered Insights, Decentralized Clinical Trials, Diversity in Clinical Trials, and Patient Engagement Among the Critical Topics to Be Showcased at Medidata’s NEXT Global 2021 Event

Tuesday, September 28, 2021 - 6:00pm

Sessions include:

Key Points: 
  • Sessions include:
    Daiichi Sankyo and AbbVie Following The Journey: Defining the Story Around Diversity in Clinical Trials
    ICON Medical Imaging Data, Privacy and AI Oh My!
  • NEXT Global attendance is free for customers, partners, and qualified members of the life sciences community.
  • Medidata thanks NEXT Global sponsors Labcorp, Syneos Health, eClinical Solutions, Capgemini, Accenture, ICON plc, CTI, Everest Clinical Research, Parexel, Advanced Clinical, Clinipace, Premier Research, and Advanced Research Associates.
  • Dassault Systmes brings value to more than 290,000 customers of all sizes, in all industries, in more than 140 countries.

Bo'ao Winhealth Rare Disease Medical Center and Ali Health Jointly Launched the "Global Drug Information Platform for Rare Diseases"

Monday, September 27, 2021 - 2:00pm

Jointly built by Bo'ao Winhealth Rare Disease Medical Center and Ali Health, the Platform aims at addressing the challenges of unavailability and unaffordability of the overseas innovative therapies facing the Chinese patients with rare diseases.

Key Points: 
  • Jointly built by Bo'ao Winhealth Rare Disease Medical Center and Ali Health, the Platform aims at addressing the challenges of unavailability and unaffordability of the overseas innovative therapies facing the Chinese patients with rare diseases.
  • "The Global Drug Information Platform for Rare Diseases is an effective exploration by multiple parties for the construction of support system for rare diseases.
  • The special policy of Boao Lecheng Pilot Zone and Bo'ao Winhealth Rare Disease Medical Center offer hope for patients.
  • For more information, please follow "Bo'ao Winhealth Rare Disease Medical Center" on Wechat.

HER2+ Breast Cancer Global Drug Forecast and Market Analysis to 2030 - ResearchAndMarkets.com

Monday, September 20, 2021 - 10:26am

The "HER2+ Breast Cancer - Global Drug Forecast and Market Analysis to 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "HER2+ Breast Cancer - Global Drug Forecast and Market Analysis to 2030" report has been added to ResearchAndMarkets.com's offering.
  • Breast cancer is the second most common cancer in the world and the most common cancer in women worldwide.
  • Human epidermal growth factor receptor 2-positive (HER2+) breast cancer constitutes approximately 20% of breast cancer cases and was historically associated with poor prognosis in the absence of effective treatments.
  • The HER2+ market is forecast to grow to $12.1B by 2030, at a Compound Annual Growth Rate (CAGR) of 1.5%.